To determine the signaling pathways leading from Met activation to metastasis and poor prognosis, we measured the kinetic gene alterations in breast cancer cell lines in response to HGF/SF. Using a network inference tool we analyzed the putative protein-protein interaction pathways leading from Met to these genes and studied their specificity to Met and prognostic potential. We identified a Met kinetic signature consisting of 131 genes. The signature correlates with Met activation and with response to anti-Met therapy (p<0.005) in in-vitro models. It also identifies breast cancer patients who are at high risk to develop an aggressive disease in six large published breast cancer patient cohorts (p<0.01, N>1000). Moreover, we have identified novel putative Met pathways, which correlate with Met activity and patient prognosis. This signature may facilitate personalized therapy by identifying patients who will respond to anti-Met therapy. Moreover, this novel approach may be applied for other tyrosine kinases and other malignancies.
References
[1]
Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768–771.
[2]
Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, et al. (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699–702.
[3]
Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, et al. (1995) Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702–705.
[4]
Rubin JS, Bottaro DP, Aaronson SA (1993) Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta 1155: 357–371.
[5]
Kamalati T, Niranjan B, Yant J, Buluwela L (1999) HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models. J Mammary Gland Biol Neoplasia 4: 69–77.
[6]
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925.
[7]
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89–103.
[8]
Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, et al. (1992) The met proto-oncogene receptor and lumen formation. Science 257: 1258–1261.
[9]
Altstock RT, Stein GY, Resau JH, Tsarfaty I (2000) Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. Cytometry 41: 155–165.
[10]
Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. (2000) Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35: 714–721.
[11]
Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, et al. (2009) Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A 106: 12909–12914.
[12]
Ponzo MG, Lesurf R, Petkiewicz S, O’Malley FP, Pinnaduwage D, et al. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106: 12903–12908.
[13]
Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, et al. (1999) Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol 21: 397–408.
[14]
Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, et al. (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82: 1513–1520.
[15]
Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, et al. (1994) Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54: 1630–1633.
[16]
Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86: 2259–2265.
[17]
Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, Camp RL, Rimm DL (2003) Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97: 1841–1848.
[18]
Chen HH, Su WC, Lin PW, Guo HR, Lee WY (2007) Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat 103: 167–175.
[19]
Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, et al. (2007) Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31: 49–58.
[20]
Zhang YW, Graveel C, Shinomiya N, Vande Woude GF (2004) Met decoys: will cancer take the bait? Cancer Cell 6: 5–6.
[21]
Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59: 111–137.
[22]
Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM (2011) HGF-independent potentiation of EGFR action by c-Met. Oncogene.
[23]
Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68: 1471–1477.
[24]
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, et al. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582–1595.
[25]
Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 140: 595–610.
[26]
Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, et al. (2009) Only a subset of met-activated pathways are required to sustain oncogene addiction. Sci Signal 2: er11.
[27]
Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, et al. (2009) Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res 16: 45–58.
[28]
Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, et al. (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56: 4063–4070.
[29]
Yosef N, Ungar L, Zalckvar E, Kimchi A, Kupiec M, et al. (2009) Toward accurate reconstruction of functional protein networks. Mol Syst Biol 5: 248.
[30]
Yosef N, Zalckvar E, Rubinstein AD, Homilius M, Atias N, et al. (2011) ANAT: a tool for constructing and analyzing functional protein networks. Sci Signal 4: pl1.
[31]
van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
[32]
Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550–13555.
[33]
Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102: 3738–3743.
[34]
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
[35]
Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953–964.
[36]
Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405–5413.
[37]
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009.
[38]
Prat A, Parker JS, Karginova O, Fan C, Livasy C, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
[39]
Gastaldi S, Comoglio PM, Trusolino L (2010) The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res 12: 208.
[40]
Hochgrafe F, Zhang L, O’Toole SA, Browne BC, Pinese M, et al. (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 70: 9391–9401.
[41]
Cronin M, Sangli C, Liu ML, Pho M, Dutta D, et al. (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53: 1084–1091.
[42]
Pauley RJ, Soule HD, Tait L, Miller FR, Wolman SR, et al. (1993) The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. Eur J Cancer Prev 2 Suppl 367–76.
[43]
Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, et al. (1999) Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 56: 91–97.
[44]
Subik K, Lee JF, Baxter L, Strzepek T, Costello D, et al. (2010) The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 4: 35–41.
[45]
Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, et al. (1993) Met expression and sarcoma tumorigenicity. Cancer Res 53: 5355–5360.
[46]
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.
[47]
Braun R, Cope L, Parmigiani G (2008) Identifying differential correlation in gene/pathway combinations. BMC Bioinformatics 9: 488.
[48]
Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, et al. (2011) Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 122: 163–170.
[49]
Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, et al. (2011) Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 13: 12–22.
[50]
Ueki T, Nishidate T, Park JH, Lin ML, Shimo A, et al. (2008) Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene 27: 5672–5683.
[51]
Taher TE, Tjin EP, Beuling EA, Borst J, Spaargaren M, et al. (2002) c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 169: 3793–3800.
[52]
Gao CF, Vande Woude GF (2005) HGF/SF-Met signaling in tumor progression. Cell Res 15: 49–51.
[53]
Keyhanian K, Edalat R, Oghalaei A, Askary N, Golshani A, et al. (2007) Effect of hepatocyte growth factor (HGF) on the level of Survivin & XIAP expression in several human cancer cell lines, after treating with DNA damaging agent. Mol Cell Biochem 304: 199–205.
[54]
Goormachtigh G, Ji Z, Le Goff A, Fafeur V (2011) Degradation of the GAB1 adaptor by the ubiquitin-proteasome pathway hampers HGF/SF-MET signaling. Biochem Biophys Res Commun 411: 780–785.
[55]
Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, et al. (2007) Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27: 2803–2808.
[56]
Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O’Mahony D, et al. (2009) Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood 113: 4016–4026.
[57]
Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, et al.. (2012) High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat.
[58]
Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A (2010) The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res 70: 1141–1153.
[59]
Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, et al. (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 108: 3761–3766.
[60]
Nandi AK, Ford T, Fleksher D, Neuman B, Rapoport AP (2007) Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53. Biochem Biophys Res Commun 358: 181–188.
[61]
Fukukawa C, Ueda K, Nishidate T, Katagiri T, Nakamura Y (2010) Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer 49: 861–872.
[62]
Reshetnikova G, Troyanovsky S, Rimm DL (2007) Definition of a direct extracellular interaction between Met and E-cadherin. Cell Biol Int 31: 366–373.
[63]
Logullo AF, Nonogaki S, Pasini FS, Osorio CA, Soares FA, et al. (2010) Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. Oncol Rep 23: 313–320.
[64]
Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, et al. (2011) Identification of early molecular markers for breast cancer. Mol Cancer 10: 15.
[65]
Sridhar SC, Miranti CK (2006) Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25: 2367–2378.
[66]
Frasor J, Chang EC, Komm B, Lin CY, Vega VB, et al. (2006) Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66: 7334–7340.
[67]
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214–218.
[68]
Hanissian SH, Teng B, Akbar U, Janjetovic Z, Zhou Q, et al. (2005) Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma. Brain Res 1047: 56–64.
[69]
Schroder K, Schutz S, Schloffel I, Batz S, Takac I, et al. (2011) Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating Nox2. Antioxid Redox Signal 15: 915–923.
[70]
Row PE, Clague MJ, Urbe S (2005) Growth factors induce differential phosphorylation profiles of the Hrs-STAM complex: a common node in signalling networks with signal-specific properties. Biochem J 389: 629–636.
[71]
Huhn S, Ingelfinger D, Bermejo JL, Bevier M, Pardini B, et al. (2011) Polymorphisms in CTNNBL1 in relation to colorectal cancer with evolutionary implications. Int J Mol Epidemiol Genet 2: 36–50.
[72]
Uluer ET, Aydemir I, Inan S, Ozbilgin K, Vatansever HS (2011) Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta Histochem.
[73]
Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Korner S, et al. (2011) Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 108: 14240–14245.
[74]
Salgia R (2009) Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol 36: S52–58.
[75]
Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, et al. (2011) Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: Understanding the aging and cancer connection. Cell Cycle 10: 4065–4073.
[76]
Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, et al. (2011) KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res 31: 2535–2539.
